FDA News: Weekly Review… June 28th

APPROVED! KENGREAL  (cangrelor) an intravenous antiplatelet drug that prevents formation of harmful blood clots in the coronary arteries, the blood vessels that supply blood to the heart. (The Medicines Company, Parsipanny, NJ, Approved 6/22/15)

Indication :  Adjunct to percutaneous coronary intervention (PCI) to reduce the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor

Effectiveness:

  • CHAMPION PHOENIX Trial –  Primary outcome measure of first occurrence of any one of the composite endpoint of all-cause mortality, myocardial infarction, ischemia-driven revascularization, and stent thrombosis within 48 hours after randomization. Kangreal vs Clopidogrel (p<0.005)
  • Two additional trials, CHAMPION PCI and CHAMPION PLATFORM were terminated early for futility

 Safety:

  • Higher Bleeding – all categories – with Kangreal vs clopidogrel.
  • Higher rate of discontinuation for bleeding higher with Kangreal.

Positioning:  While Kengreal provides another treatment option for patients – it requires intravenous administration and causes increased bleeding vs clopidogrel, an orally administered antiplatelet that is generic.  Innovative Payor strategy will be important to effectively differentiate the drug.

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm452172.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

Post-Marketing Safety Assessments and Label Updates:

Analysis Effective Pharmacovigilance and Signal Detection (FDA and Sponsor initiated) critical for benefit/risk assessment and appropriate labeling for marketed products. Highlights the importance of use of the MedWatch program by patients and health care professionals.

 Capturesafety

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s